Assessing Bone Disorders in Kidney Transplant Recipients
Studies bone measurements to better assess mineral and bone disease in adults after kidney transplant.
Plain-language title generated from the registry record
Registry title: Assessment of Mineral and Bone Disorders in Kidney Transplant Recipients
Key facts
- Where
- Iași, RomaniaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for three groups: adults on long-term haemodialysis, adults with a kidney transplant, and adults with osteopenia or osteoporosis. It studies bone and mineral problems.
- Age
- 20-70 years for dialysis and kidney transplant groups; 50-70 years for the osteopenia or osteoporosis group.
- Sex
- All. The osteopenia or osteoporosis group is men and postmenopausal women.
- Disease stage
- Dialysis group: on haemodialysis for at least 12 months. Transplant group: successful kidney transplant at least 12 months ago. Third group: primary osteopenia or osteoporosis.
- Earlier treatment
- Dialysis group: no active bone treatment (calcium and vitamin D are allowed). Transplant group: any immunosuppression regimen, any history before the transplant. The osteopenia or osteoporosis group: no long-term glucocorticoid treatment (more than 7.5 mg prednisone or equivalent for at least 3 months).
Main reasons for not taking part
- Ongoing cancer treatment or recent cancer
- Cirrhosis
- Recent major fractures
- Transplant of an organ other than a kidney
- Pregnancy or breast-feeding
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 70 years old?
Source: NCT07141043, who can take part
Where in Romania
- University of Medicine and Pharmacy "Grigore T. Popa"Iași, RomaniaContact: Nada Akad, Dr.Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Grigore T. Popa University of Medicine and Pharmacy
- Trial code
- NCT07141043
- Record updated
- 26 August 2025
- Original description
This study aims to integrate bone measurements (including bone turnover markers (BTM), bone mineral density (BMD) measurement, vertebral fracture assessment (VFA), trabecular bone score (TBS) ) commonly used in the general population for primary osteoporosis evaluation to enhance the assessment of CKD-MBD.Read full original descriptionShow less
New Directions and Perspectives in the Assessment of Mineral and Bone Disorders in Kidney Transplant Recipients
This study aims to integrate bone measurements (including bone turnover markers (BTM), bone mineral density (BMD) measurement, vertebral fracture assessment (VFA), trabecular bone score (TBS) ) commonly used in the general population for primary osteoporosis evaluation to enhance the assessment of CKD-MBD.
Inclusion: HD group: Patients undergoing HD for at least 12 months, aged 20-70 years, after signing an informed consent; KTR group: Patients with successful KTx performed at least 12 months prior to their enrollment, aged 20-70 years old, after signing an informed consent. Subjects will be eligible for inclusion regardless of KTx immunosuppression regimen, pre-transplantation history, history of pre-transplant dialysis, or whether the kidney donation was from a living or deceased donor; GPO group: men and postmenopausal women diagnosed with primary osteopenia or osteoporosis, aged 50-70 years old, after signing an informed consent.
Exclusion: GPO group: The same as for HD + diabetes mellitus + prolonged glucocorticoid therapy (>7.5 mg Prednisone or equivalent for at least 3 months); HD group: Treatment with active bone therapies (excluding calcium and vitamin D); ongoing cancer treatment or recent history of malignancy, cirrhosis, recent major fractures, patients who have received transplants other than kidney, secondary causes of osteoporosis (other than CKD or transplant-related: primary hyperparathyroidism, hyperthyroidism, congenital bone disorders, sarcoidosis, severe bone trauma, malignant tumors, inflammatory bowel disease, endogenous Cushing syndrome, anti-estrogen/anti-androgen therapy, and anorexia nervosa), pregnancy and breast-feeding; KTR group: The same as for HD + return to dialysis + acute graft rejection.